Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

SARS-CoV-2 readily infects human intestinal cells in a laboratory model

A new Dutch study available on bioRxiv uses differentiated human small intestinal organoids in vitro to demonstrate that intestinal epithelium supports the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and elicits a strong generic immune response.

27 Apr 2020

Rice University looks to ‘trap and zap’ SARS-CoV-2 in wastewater

A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.

27 Apr 2020

Goblet cells in the human nasal passage may play key role in enabling COVID-19 infections

Two significant international studies involving hundreds of scientists, including a human geneticist at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that specific cells in the human nasal passage shaped like a champagne glass, known as goblet cells, may play a significant role in enabling COVID-19 infections.

24 Apr 2020

Scientists are developing synthetic COVID-19 antibody to treat sick patients

A team of researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). This antibody is intended to block the virus from entering human lung cells, and would be another potential treatment option for COVID-19.

24 Apr 2020

SARS-CoV-2 targets specific cells in the lung, nasal passage, and intestine

Now, the researchers from the Massachusetts Institute of Technology (MIT) have identified specific types of cells that are targets of the SARS-CoV-2 that causes the COVID-19 pandemic. The findings of the study published in the journal Cell may help in developing novel therapeutics to combat the deadly viral infection.

23 Apr 2020

RAS inhibitors and COVID-19 severity in hypertensive patients

A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.

23 Apr 2020

Study identifies key nose cells as likely COVID-19 virus entry points

Two specific cell types in the nose have been identified as likely initial infection points for COVID-19 coronavirus. Scientists discovered that goblet and ciliated cells in the nose have high levels of the entry proteins that the COVID-19 virus uses to get into our cells.

23 Apr 2020

Scientists identify cells likely targeted by novel coronavirus

Researchers at MIT; the Ragon Institute of MGH, MIT, and Harvard; and the Broad Institute of MIT and Harvard; along with colleagues from around the world have identified specific types of cells that appear to be targets of the coronavirus that is causing the Covid-19 pandemic.

22 Apr 2020

COVID-19 unlikely to be transmitted through semen, study shows

COVID-19 is unlikely to be spread through semen, according to University of Utah Health scientists who participated in an international study of Chinese men who recently had the disease.

22 Apr 2020

COVID-19 and immunodeficiency

COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly infectious disease. As of today, over 170,000 people worldwide have succumbed to the infection. Reports have shown that some comorbidities and illnesses raise the risk of getting infected and also influence the severity of the disease. Having a compromised immune system can also drastically raise the risk of getting COVID-19.

21 Apr 2020

Role of ACE/ARB inhibitors in the treatment of COVID-19

A new opinion piece published in the journal Circulation Research in April 2020 defends the use of antihypertensive drugs called ACE inhibitors and ARBs in patients with pandemic viral pneumonia called COVID-19.

20 Apr 2020

ACE2 receptor expression by SARS-CoV-2 across different animal species

A new report published on the preprint server bioRxiv in April 2020 reports that several species of animals can be infected with relative ease by the SARS-CoV-2 virus that is the causative agent of the currently raging COVID-19 pandemic. This casts much light on the possible natural hosts and routes of transmission of this virus.

20 Apr 2020

Mutations in novel coronavirus make it more dangerous

A new report published on the preprint server medRxiv in April 2020 reveals that the novel coronavirus SARS-CoV-2 shows the presence of new mutations acquired within infected human cases, which significantly increase its ability to cause human disease.

20 Apr 2020

ACE2-TMPRSS2 profiling indicates tissue vulnerability to SARS-CoV-2 infection

A new study published in April 2020 on the preprint server bioRxiv reports that the different levels of susceptibility of various organs to viral attack by the SARS-CoV-2 virus causing the huge pandemic of COVID-19 sweeping around the world can be predicted from the level of expression of two molecules, the ACE2 receptor, and the TMPRSS2 protein.

20 Apr 2020

Do ACE inhibitors increase SARS-CoV-2 binding to ACE2?

The COVID-19 pandemic has forced clinicians and academicians to intensive research to find evidence for many conventional therapies. A new round-up editorial published in the journal Cardiovascular Research in April 2020 summarizes the current clinical grounds for and against the use of the commonly used angiotensin axis inhibitors in patients with COVID-19.

20 Apr 2020

Male-female cardiac repair differences found in heart failure survival after heart attack

The short-term acute inflammatory response triggered to mend injured cardiac tissue following a heart attack can lead to weakening of the heart's pumping function if the inflammation remains active over the long-term.

20 Apr 2020

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

A new study published in the journal bioRxiv in April 2020 reports the identification of a promising multidrug treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for causing COVID-19 disease. The team predicts that this combination will prevent the virus from reproducing, hence both halting the transmission and progress of the disease.

19 Apr 2020

Trial to evaluate how blood pressure medications affect outcomes among COVID-19 patients

A new trial led by the Perelman School of Medicine at the University of Pennsylvania will evaluate whether the use of medications to treat high blood pressure affect outcomes among patients who are prescribed the medication and hospitalized with COVID-19.

16 Apr 2020

Anosmia (loss of smell) confirmed as a clinical feature of COVID-19

Earlier last month, the association of ear, nose, and throat (ENT) specialists in the UK issued a public statement advising patients with a sudden loss of smell or taste to get tested for COVID-19. They cited not only their own observations but those from numerous other ENT consultants the world around. A review of multiple papers on the sinus and nasal symptoms and signs related to the diagnosis of COVID-19, published in April 2020, in the journal Laryngoscope Investigative Otolaryngology, reiterates this finding.

15 Apr 2020

ACE2 genetic variants may influence coronavirus disease progression

Researchers in British Columbia have identified a set of gene variants that are likely to influence disease progression from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to COVID-19 disease.

15 Apr 2020